Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2011

Heuckmann Johannes M, Hölzel Michael, Sos Martin L, Heynck Stefanie, Balke-Want Hyatt, Koker Mirjam, Peifer Martin, Weiss Jonathan, Lovly Christine M, Grütter Christian, Rauh Daniel, Pao William, Thomas Roman K

Abstract excerpt

PURPOSE: EML4-ALK fusions define a subset of lung cancers that can be effectively treated with anaplastic lymphoma kinase (ALK) inhibitors. Unfortunately, the duration of response is heterogeneous and acquired resistance limits their ultimate efficacy. Thus, a better understanding of resistance mechanisms will help to enhance tumor control in EML4-ALK-positive tumors. EXPERIMENTAL DESIGN: By applying orthogonal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Microtubule-Associated Proteins

Share to Neuroblastoma

Share to Oncogene Proteins, Fusion

Share to Pyrazoles

Share to Pyridines

Share to Serine Endopeptidases

Source

Open in PubMed Open full text

Identifiers

PMID: 21948233
DOI: 10.1158/1078-0432.CCR-11-1648
PMCID: PMC3382103

Genes

ALK
EML4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.PMID 21948233Read ↗

Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis ScreenSemantic proximity Read ↗

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.Semantic proximity Read ↗

A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC.Semantic proximity Read ↗

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.Semantic proximity Read ↗

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.Semantic proximity Read ↗

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.Semantic proximity Read ↗

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.Semantic proximity Read ↗

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.Semantic proximity Read ↗

EML4-ALK G1202R and EML4-ALK L1196M mutations induce crizotinib resistance in non-small cell lung cancer cells through activating epithelial-mesenchymal transition mediated by MDM2/MEK/ERK signal axis.Semantic proximity Read ↗

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.Semantic proximity Read ↗

Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations.Semantic proximity Read ↗

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.